Whole gene expression profile in blood reveals multiple pathways deregulation in R6/2 mouse model by Daniela Diamanti et al.
Diamanti et al. Biomarker Research 2013, 1:28
http://www.biomarkerres.org/content/1/1/28SHORT REPORT Open AccessWhole gene expression profile in blood reveals
multiple pathways deregulation in R6/2 mouse
model
Daniela Diamanti1*, Elisa Mori1, Danny Incarnato2, Federico Malusa1, Costanza Fondelli1, Letizia Magnoni1
and Giuseppe Pollio1Abstract
Background: Huntington Disease (HD) is a progressive neurological disorder, with pathological manifestations in
brain areas and in periphery caused by the ubiquitous expression of mutant Huntingtin protein. Transcriptional
dysregulation is considered a key molecular mechanism responsible of HD pathogenesis but, although numerous
studies investigated mRNA alterations in HD, so far none evaluated a whole gene expression profile in blood of R6/
2 mouse model.
Findings: To discover novel pathogenic mechanisms and potential peripheral biomarkers useful to monitor disease
progression or drug efficacy, a microarray study was performed in blood of R6/2 at manifest stage and wild type
littermate mice. This approach allowed to propose new peripheral molecular processes involved in HD and to
suggest different panels of candidate biomarkers. Among the discovered deregulated processes, we focused on
specific ones: complement and coagulation cascades, PPAR signaling, cardiac muscle contraction, and dilated
cardiomyopathy pathways. Selected genes derived from these pathways were additionally investigated in other
accessible tissues to validate these matrices as source of biomarkers, and in brain, to link central and peripheral
disease manifestations.
Conclusions: Our findings validated the skeletal muscle as suitable source to investigate peripheral transcriptional
alterations in HD and supported the hypothesis that immunological alteration may contribute to neurological
degeneration. Moreover, the identification of altered signaling in mouse blood enforce R6/2 transgenic mouse as a
powerful HD model while suggesting novel disease biomarkers for pre-clinical investigation.
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Huntington disease (HD) is an autosomal dominant neu-
rodegenerative disorder characterized by progressive at-
rophy of specific brain areas with consequent alterations
of motor and cognitive functions, including psychiatric
disturbances, weight loss, as well as metabolic, neuroen-
docrine and immunological alterations [1-3]. The cause
of this fatal disease is an aberrant expansion of CAG tri-
nucleotide in the exon 1 of HTT gene, translating into a* Correspondence: ddiamanti@sienabiotech.it
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reproduction in any medium, provided the orgain-of-function and loss-of-function to wild type
huntingtin protein. In healthy individuals, CAG number
is included in the range of 6 to 26, while HD patients
have more than 36 Gln stretch [1] with an inverse rela-
tionship between polyQ length and the age of onset. The
aberrant polyQ tract results in Huntingtin protein
misfolding, which generates insoluble intracellular inclu-
sions and aggregates, important hallmarks of the disease.
Despite extraordinary efforts in understanding the HD
pathogenesis, the exact molecular mechanisms responsible
for this devastating disorder are still unknown and probably
multiple parallel processes may contribute, representing po-
tential therapeutic targets [4,5]. Striking evidences support
an important role of transcriptional abnormalities in HDal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and its aggregates could modulate gene transcription by
entering the nucleus and altering the transcriptional ma-
chinery either directly, through DNA binding [7], or se-
questering important transcription factors [8].
Even though no animal models currently in use en-
compass all disease features, transgenic mice carrying ei-
ther full length or mut-HTT fragments represent an
invaluable instrument to study pathological mechanisms
and to test efficacy and toxicity of small molecules in
pre-clinical settings [9-11]. Numerous behavioral and
neurological symptoms similar to what seen in HD pa-
tients have been also observed in transgenic mouse
models [11,12] including those expressing only short
fragments of mut-HTT, as R6/2 mice [13]. R6/2 is one
of the first HD transgenic mouse model created, ex-
pressing only the N-terminal fragment of HTT (exon 1)
and it is characterized by short survival and develop-
ment of pathological features mimicking human stages
of disease [13,14]. For this reason, transcriptional and
behavioral alterations have been intensely studied in
R6/2, which has being commonly employed not only in
pre-clinical drug testing but also in peripheral investiga-
tions, often realized in parallel with HD patients [15,16].
Stemming from those observations, although HD is
mainly a CNS disorder, ubiquitous expression of both
normal and mut-HTT in the whole body [17] has moved
the attention toward peripheral dysfunctions, increasing
the knowledge on HD etiology and other disease mani-
festations, and aiding the finding of new biomarkers
[18,19], as evidenced by the flourishing number of tran-
scriptional and proteomic studies conducted in HD
blood [16,20-24].
In this study, we investigated transcriptional dysregulations
occurring in R6/2 and wild type littermate mouse blood
to reinforce previous observations derived from human
studies and to discover novel pathological processes
and candidate biomarkers, useful in pre-clinical investi-
gations and in designing therapeutic trials. The tran-
scriptional alterations detected in blood were also
analyzed in brain to identify a possible link with central
pathological mechanisms, and in other peripheral tis-
sues, like skeletal muscle and skin, to validate them as
additional sources of potential biomarkers.
Findings
Primary analysis of microarrays
To discover differential peripheral gene expression be-
tween R6/2 and WT littermate mice, blood samples
were collected at 16 weeks of age, when mutant mice
were starting to show neurological signs of decline, like
abnormal motor behavior and body weight loss, all char-
acteristics of symptomatic state of the HD pathology.
Transcriptional investigation was carried through amicroarray study performed on individual blood sample
of four R6/2 and three WT mice. Microarray analysis
showed approximately 2200 transcripts significantly
modulated between R6/2 and WT mice, according to se-
lection criteria of p-value (p) lower than 0.05 and abso-
lute fold change (abs FC) higher than 1.3 (Figure 1A).
Among these, 1072 probe sets were up-regulated and
1164 were down-regulated. A limited number of tran-
scripts (133) resulted significantly altered in blood with a
p < 0.05 and high FC (abs FC > 2). A selection of these
most differentially expressed (p < 0.001; abs FC > 2)
genes are reported in Figure 1B.
GSEA analysis of differentially expressed genes
In order to highlight relevant processes that could be al-
tered in blood, we applied Gene Set Enrichment Analysis
(GSEA) method on the same dataset. This computa-
tional method identifies groups of genes with modest
but coordinate changes in the expression between phe-
notypes by utilizing all transcripts of a microarray
dataset and discovering significant differences in terms
of pathways or gene sets associated with a particular bio-
logical function. Microarray analysis was performed
using KEGG, BioCarta and Reactome pathway collec-
tions of MSigDB and was enforced by Biological Pro-
cesses of GeneOntology.
Analyzing KEGG, 92 gene sets resulted up-regulated
and 77 down-regulated in mutant mice with respect to
wild type mice, and among them, 19 pathways were sig-
nificantly enriched in R6/2, while 2 were significantly
enriched in wild type, having FDR < 25% (Table 1).
Reactome database, which contains a wider number of
gene sets with respect to KEGG, showed a total number
of 309 up-regulated collections, 14 of them with FDR <
25%, and 169 down-regulated collections, but none with
a significant modulation (Table 1). By using BioCarta
significant modulations were revealed only in 3 up-
regulated gene sets among 79 positively regulated and
57 negatively regulated (Table 1).
Similar findings were obtained by analyzing entire
microarray expression dataset in terms of biological pro-
cesses of GeneOntology collections. In particular, 20 of
these differentially modulated processes were linked to
metabolism (Additional file 1: Table S1). Results con-
firmed alteration of metabolic processes in mutant mice
as well as coagulation impairment and amino acid, lipid
and fatty acid metabolism dysfunctions. Moreover, regu-
lation of muscle and heart contraction processes
emerged among enriched processes in WT mice.
To understand information derived from GSEA, we
analyzed in details pathways markedly modulated in
KEGG database, focusing on the two top enriched col-
lections in R6/2, namely “complement and coagulation
cascade” and “PPAR signaling”, together with the two
Figure 1 Microarray results. Figure shows results of microarray analysis performed on four R6/2 versus three WT mice using LIMMA package:
(A) Volcano plot shows the –log10 of p-values against the genes biological effect expressed as log2 transformed fold change. Cutoff values are
set to p < 0.05 and abs FC > 1.3. (B) Bi-dimensional cluster (obtained by using correlation and Euclidean distances between genes and strains,
respectively, and applying average linkage method) shows the 23 most significant differentially expressed probe sets [p < 0.001 and abs FC > 2].
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muscle contraction” and “dilated cardiomyopathy”, em-
phasizing existing relationships with HD pathology.
Complement and coagulation cascade
Complement and coagulation cascade pathway resulted
altered in R6/2 mice in the three database employed
with GSEA. Pathway core enrichment obtained from our
analysis comprised numerous components of comple-
ment system and serpins, as well as many coagulation
factors, that resulted up-regulated in blood of R6/2 mice
with respect to WT (Figure 2; detailed core enrichment
in Additional file 2: Table S2).
The complement system is involved in the first line of
host defense against pathogens [25]. Consisting of sol-
uble and membrane embedded proteins, it is a compo-
nent of the innate immune response, that acts in
peripheral tissues and in the brain. Although a protective
role linked to clearance of cellular debris has been
assigned to several components of the cascade, a rele-
vant effect of its activation in brain is that it may con-
tribute to neuro-inflammation and neuronal loss in
neurodegenerative disorders as HD and Alzheimer’s dis-
ease [26]. Indeed, an increased number of works debate
on the immune system activation in HD [2,27]. Most of
them are focused on the complement cascade impair-
ment by accurate investigations at transcriptional and
proteomic level, both in blood and brain, to discover po-
tential biomarkers or causative factors of the pathology,
respectively [19,23,28]. Here, we discovered for the first
time transcriptional alteration of numerous components
of the complement system in whole blood of an HD
mouse model at manifest stage. Although previous tran-
scriptional studies conducted in HD patients blood[20,21] did not report abnormalities of this pathway, our
findings agree with a multi-approaches proteomic inves-
tigation performed in HD human plasma samples [23].
In Dalrymple et al. [23], several proteins including some
complement components, as C9, were identified as pos-
sible disease progression biomarkers, confirming the
involvement of acute-phase response and consequent
activation of complement cascade in HD patients. In
our investigation, no significant alteration of interleu-
kins and cytokines mRNAs was observed in R6/2 blood
at this stage, differently from what has been measured
in plasma of HD patients and serum of HD animal
models [19,29].
The identification of complement and coagulation cas-
cade signaling in murine blood may enforce R6/2 trans-
genic mouse as HD model to discover pharmacodynamic
and disease peripheral biomarkers useful in pre-clinical in-
vestigation. Moreover, recent evidences focusing on
druggability of pathway components [30,31], evaluated
complement factors as potential targets for the treatment
of autoimmune and inflammatory diseases, including neu-
rodegenerative disorders.
PPAR signaling
Considering KEGG database results, PPAR signaling was
the second best enriched pathway in mutant mice. This
is intrinsically linked to other downstream processes
emerging in the KEGG list of R6/2 up-regulated path-
ways, such as primary bile acid biosynthesis, biosynthesis
of unsaturated fatty acids and fatty acid metabolism, or
other pathways related to amino acid metabolism or
synthesis (Table 1). Additionally, most of them resulted
modulated in the analysis performed by Reactome
database (Table 1). A similar metabolic profile was also
Table 1 GSEA canonical pathways results on three different database (KEGG, Reactome and BioCarta)
Gene set name SIZE ES NES NOM p-val FDR q-val FWER p-val
KEGG COMPLEMENT AND COAGULATION CASCADES 61 0.69 2.56 0.000 0.000 0.000
PPAR SIGNALING PATHWAY 60 0.56 2.02 0.000 0.004 0.006
GLYCINE SERINE AND THREONINE METABOLISM 29 0.60 1.87 0.002 0.023 0.057
PRIMARY BILE ACID BIOSYNTHESIS 15 0.69 1.77 0.006 0.044 0.137
RIBOSOME 82 0.45 1.73 0.000 0.052 0.199
LYSINE DEGRADATION 43 0.48 1.63 0.007 0.126 0.483
HISTIDINE METABOLISM 28 0.53 1.62 0.020 0.110 0.488
SYSTEMIC LUPUS ERYTHEMATOSUS 54 0.46 1.62 0.007 0.101 0.505
PEROXISOME 73 0.43 1.60 0.002 0.105 0.565
PENTOSE PHOSPHATE PATHWAY 23 0.55 1.59 0.013 0.100 0.582
BUTANOATE METABOLISM 30 0.51 1.59 0.007 0.095 0.598
CYSTEINE AND METHIONINE METABOLISM 33 0.47 1.54 0.026 0.131 0.736
BIOSYNTHESIS OF UNSATURATED FATTY ACIDS 18 0.55 1.53 0.035 0.134 0.770
TYROSINE METABOLISM 35 0.46 1.51 0.031 0.144 0.822
PRION DISEASES 32 0.47 1.51 0.024 0.140 0.831
ONE CARBON POOL BY FOLATE 16 0.55 1.47 0.043 0.177 0.910
SELENOAMINO ACID METABOLISM 25 0.48 1.46 0.047 0.171 0.916
FATTY ACID METABOLISM 33 0.45 1.44 0.047 0.193 0.948
AMINOACYL TRNA BIOSYNTHESIS 41 0.42 1.40 0.048 0.241 0.977
CARDIAC MUSCLE CONTRACTION 69 −0.5 −1.83 0.000 0.044 0.051
DILATED CARDIOMYOPATHY 87 −0.46 −1.74 0.000 0.075 0.163
REACTOME FORMATION OF FIBRIN CLOT CLOTTING CASCADE 31 0.7 2.20 0.000 0.002 0.001
BILE ACID AND BILE SALT METABOLISM 23 0.73 2.18 0.000 0.001 0.001
COMPLEMENT CASCADE 23 0.71 2.10 0.000 0.003 0.007
LIPOPROTEIN METABOLISM 26 0.67 2.05 0.000 0.007 0.019
RESPONSE TO ELEVATED PLATELET CYTOSOLIC CA2 74 0.53 2.01 0.000 0.010 0.034
CHYLOMICRON MEDIATED LIPID TRANSPORT 16 0.73 2.00 0.000 0.009 0.039
INTRINSIC PATHWAY 17 0.73 1.99 0.000 0.008 0.040
METABOLISM OF AMINO ACIDS AND DERIVATIVES 188 0.45 1.98 0.000 0.009 0.052
LIPID DIGESTION MOBILIZATION AND TRANSPORT 41 0.58 1.95 0.002 0.011 0.070
SYNTHESIS OF BILE ACIDS AND BILE SALTS 18 0.69 1.91 0.004 0.016 0.109
SULFUR AMINO ACID METABOLISM 24 0.61 1.84 0.002 0.035 0.239
PEPTIDE CHAIN ELONGATION 81 0.45 1.74 0.000 0.094 0.548
CLEAVAGE OF GROWING TRANSCRIPT IN THE TERMINATION REGION 31 0.51 1.63 0.011 0.238 0.888
TRANSCRIPTIONAL ACTIVITY OF SMAD2 SMAD3 SMAD4 HETEROTRIMER 36 0.49 1.62 0.007 0.248 0.917
BIOCARTA COMP PATHWAY 16 0.75 2.02 0.000 0.021 0.017
INTRINSIC PATHWAY 23 0.67 2.00 0.000 0.012 0.019
TOB1 PATHWAY 19 0.61 1.70 0.011 0.224 0.412
Table shows statistically up-regulated and down-regulated pathways in R6/2 versus WT mice, and for everyone, number of genes (size) identified in the
microarrays, enrichment score (ES), normalized enrichment score (NES), nominal p-value (NOM p-val), false discovery rate (FDR q-val), familywise-error rate
(FWER p-val).
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model [24].
Peroxisome proliferator-activated receptors, PPARs, be-
long to the nuclear hormone receptor family, comprisingPPARa, PPARg, PPARb/d, and are localized in different
tissues where they influence distinct processes. PPARs
are ligand-depend transcription factors that form
heterodimeric complexes with retinoid-X-receptor RXR,
Figure 2 Complement and coagulation cascades pathway from KEGG. Genes are colored according to their GSEA calculated scores in R6/2
versus WT analysis (signal-to-noise): the most marked red genes belong to the core enrichment.
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carbohydrate, amino acid and lipid metabolism. Figure 3
shows target genes altered in R6/2 blood and belonging to
PPAR signaling core enrichment and cognate down-
stream processes (detailed core enrichment in Additional
file 3: Table S3). The impairment of this signaling has been
already seen in different tissues of HD patients and models
[32]. It can be noted that many of the genes that contrib-
ute to enrich this collection are apolipoproteins, fatty acid
binding proteins, CYP genes as well as the same PPARsand RXR. In particular, GSEA revealed adipose tissue dys-
function and adipocitokine signaling alteration that have
been already detected in R6/2 mice, where reduced
adipokine levels and PPARg target genes linked to adipo-
cyte function and differentiation were observed [33].
The other metabolic processes that emerged as altered
in R6/2 blood are well-known for being deregulated in
HD. Indeed, we found lipid-linked signaling like fatty
acids, bile acids and cholesterol metabolism. Altered
cholesterol pathway and its biosynthesis were deeply
Figure 3 PPAR signaling pathway from KEGG. Genes are colored according to their GSEA calculated scores: the most marked red genes
belong to the core enrichment.
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tients and animal models, both in peripheral tissues and
in CNS [35], demonstrating that cholesterol might have
a pivotal role in HD pathogenesis. Moreover, cholesterol
dysfunction is closely associated with lipid, triglyceride
and fatty acid metabolism that are also impaired in HD
[36]. In conclusion, evidences of PPAR signaling impair-
ment in R6/2 blood, mirroring numerous HD systemic
metabolic abnormalities [3], may contribute to the iden-
tification of new pathogenic mechanisms. Drugs against
lipid dysregulation have been already tested in HD and
they should be supported by disease biomarkers as PPAR
target genes, to monitor therapeutic efficacy.
Cardiac muscle contraction and dilated cardiomyopathy
Among all 77 gene set collections enriched in wild type
phenotype within KEGG database, only two resulted
significantly modulated: dilated cardiomyopathy andcardiac muscle contraction pathways (Figure 4 and 5).
Interestingly, other similar pathways (hypertrophic
cardiomyopathy and arrhythmogenic right ventricular
cardiomyopathy) appeared in the list of modulated col-
lections but with FDR > 25%, p < 0.1. In resulting GSEA
core enrichment of cardiac muscle contraction (Figure 5;
Additional file 4: Table S4), we found genes linked to
calcium efflux and voltage (Slc8a1, Cacna1f, Cacng1,
Cacng3, Cacna1s and Cacng6), or expressed in mito-
chondria and involved in oxidation-reduction processes
(Cox6b2, Cox7b2, Cox6a2 and Cox7a1) as well as genes
contributing to the structural integrity of muscle fibers
(Myh7, Myh6, My13 and My12). Moreover, in dilated
cardiomyopathy pathway core enrichment (Figure 4;
Additional file 5: Table S5), integrins (Itga1, Itga10, Itga8
and Itgb6) and cellular components of troponin system
(Tnni3, Tnnc1 and Tnnt2) appeared modulated, besides
Cox and Myh genes.
Figure 4 Dilated cardiomyopathy pathway from KEGG. Genes are colored according to their GSEA calculated scores.
Diamanti et al. Biomarker Research 2013, 1:28 Page 7 of 14
http://www.biomarkerres.org/content/1/1/28The two processes found down-regulated in R6/2 blood
are related to heart contraction performance, which is
monitored by cardiac myocytes excitation with the main-
tenance of cellular homeostasis through Na+ and Ca2+
fluxes. Ca2+ homeostasis imbalance is considered a rele-
vant cause of many neurodegenerative disorders, including
HD [37,38], where impairment of Ca2+ physiological
equilibrium is generally followed by progressive heart
failure and sudden cardiac death. Additionally, Ca2+
handling defects may exacerbate mitochondrial dys-
functions [39,40], considered being a relevant mechan-
ism in HD pathogenesis [41], and hence contributing to
cardiac failure too [42].
A fascinating remark is that, even if our data were
generated from a whole genome expression analysis
performed in blood, modulation of these two pathways
suggests evidences of cardiac dysfunction in R6/2 mice.
Nevertheless, although Huntington’s disease is a neuro-
logical disorder, cardiac failure is an important cause of
death in a high percentage of HD patients (over 20%)
[43]. In addition, a recent work showed direct evidences
of cardiac dysfunction in R6/2 [44], highlighting an
in-vivo impairment of numerous cardiac functions, in-
cluding myocardial contractility. Our finding agree withwhat has been previously demonstrated by Mihm et al.
[45], about cardiotoxic effects coming from peripheral
mut-HTT expression. This study displayed that mut-HTT
expression in R6/2 cardiomyocytes could result in severe
cardiac systolic and diastolic impairment, showing parallel
changes between cardiac and neurological symptoms, and
suggesting the use of cardiovascular performance indi-
cators as “state biomarkers” of disease progression.
Here, we identified for the first time in HD blood a
set of deregulated genes involved in cardiac patho-
physiology that should be useful to monitor a drug
therapy addressing this HD symptom. Peripheral blood
gene expression profiling has been already applied to
assess some cardiovascular diseases, as myocardial in-
farction [46] relying on the ability of blood to operate
as a sensor able to capture physiological and patho-
logical modifications, transforming them in gene ex-
pression changes [47].
RT-qPCR
To validate microarray results derived from GSEA, we
tested the expressions of selected genes in blood samples
through RT-qPCR. For this purpose, mouse blood sam-
ples were pooled as indicated in methods section. This
Figure 5 Cardiac muscle contraction pathway from KEGG. Genes are colored according to their GSEA calculated scores.
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Peng et al. [48]. We analyzed two genes for each men-
tioned pathway, that were also included in the group of
transcripts significantly modulated between R6/2 and
WT mice in microarrays (abs FC > 1.3 and p < 0.05). The
selected genes consisted of C3 and Serping1, employed
to test immunological hypothesis, Fabp1 together with
Slc27a2 to confirm peripheral involvement of PPAR sig-
naling, and Tmp2 and Slc8a1 for validation of cardiacTable 2 Selected genes investigated by RT-qPCR
Gene symbol ENTREZ ID GENE NAME
Tpm2 22004 tropomyosin 2, beta
Slc8a1 20541 solute carrier family 8 (sodium/calcium exch
C3 12266 complement component 3
Serping1 12258 serine (or cysteine) peptidase inhibitor, clad
Slc27a2 26458 solute carrier family 27 (fatty acid transport
Fabp1 14080 fatty acid binding protein 1, liver
Table reports name, symbol and entrez ID (obtained from NCBI database) of each g
value (p) obtained by microarray statistical analysis (Section Methods) are also showdysfunction (Table 2). This selection was limited to
genes with expression levels detectable by RT-qPCR.
All genes were tested by RT-qPCR on the same blood
samples used for microarray assay and data were nor-
malized on four reference genes. Normalized expression
levels confirmed the modulation observed in microarray
(reported in Table 2); in detail, C3, Serping1, Slc27a2,
and Fabp1 resulted up-regulated in R6/2 mutant vs WT
mice, while Tpm2 and Slc8a1 showed down-regulation,Affy Id R6/2 vs WT FC R6/2 vs WT p
1425028_a_at -1.8 0.016
anger), member 1 1437675_at -1.36 0.047
1423954_at 4.51 0.000
e G, member 1 1416625_at 2.6 0.009
er), member 2 1416316_at 3.27 0.000
1448764_a_at 20.35 0.018
ene. Corresponding Affy id together with relative Fold Change (FC) and p-
ed.
Figure 7 RT-qPCR in skin. Expression levels of selected genes were
tested in abdominal skin of mice: differences between R6/2 and WT
are not statistically significant. Slc27a2 was measurable in all R6/2
samples and only in one WT mouse; in 2 WT mice where expression
was too low to be quantifiable, the values were replaced with
detection limit of the qPCR machine: the levels in R6/2 resulted in
strong up-regulation with respect to WT. Fabp1 was not
detectable (N.D.).
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These results validated peripheral pathway alterations
obtained by GSEA, mirroring the fold changes of micro-
array analysis. Moreover, our data agreed with the
dysregulation of complement components that was pre-
viously observed in HD patients plasma [23]. On the
contrary, in a recent work, C3 plasma protein level in
R6/2 was found not significantly modulated [49] prob-
ably due to the different age of animals in our study with
respect to theirs. To validate other candidate matrices
often employed as source of biomarkers, and to compare
peripheral transcriptional alterations, expression levels
of the selected genes were investigated in other periph-
eral tissues, skeletal muscle and skin, where the presence
of mut-HTT and polyQ inclusions has been demon-
strated [17]. Gene expression alteration has been already
investigated in HD skeletal muscle [50-52], but not
yet in HD skin, although this tissue has been utilized
in transcriptional studies [53]. In our study, C3 and
Serping1 presented the same modulations in blood and
in skin samples but these were not statistically signifi-
cant (Figure 7); on the contrary, statistically significant
down-regulation of these two genes was highlighted in
R6/2 skeletal muscle with respect to wild type (Figure 8).
Slc27a2 was not expressed in skin of wild type mice but
it was quantifiable only in R6/2 (Figure 7); average
up-regulation was also noticed on skeletal muscle sam-
ples but with high variability (Figure 8). Slc27a2 over-
expression occurring only in mutant mice allowed us
to hypothesize a probable perturbation of fatty acid
metabolism in periphery. Fabp1 was not quantified in
these peripheral tissues. Tpm2 and Slc8a1 were not sig-
nificantly modulated in skeletal muscle or skin samplesFigure 6 RT-qPCR in blood. RT-qPCRs were performed in pooled
blood samples, so statistical test was not applied. Normalized
expression levels of selected genes confirmed, in blood, the
modulation previously observed in microarray, reported in Tab. 3.
Since Fabp1 was measurable in R6/2 but not in WT, this last value
was replaced with detection limit of the qPCR machine: the levels in
R6/2 resulted in strong up-regulation with respect to WT.(Figure 7 and 8). Nevertheless, our data partially con-
firmed a transcriptional modulation for Tpm2, which in
a previously published work [52] was included in the top
75 decreasing genes in R6/2 quadriceps muscle. There-
fore, skeletal muscle may represent a suitable source to
investigate peripheral transcriptional alterations; instead,
the provided data were not robust enough to validate
skin for this purpose. Moreover, this finding suggested
that complement pathway is impaired also in skeletal
muscle, and the subsequent immune response activation
may contribute to muscular atrophy, together with the
previously described molecular mechanisms of apoptosis
and autophagy [50,52].Figure 8 RT-qPCR in skeletal muscle. Expression levels of selected
genes were tested in skeletal muscle: only C3 and Serping1 showed
significant down-regulation. Fabp1 was not detectable (N.D.)
(*Student’s t-test p < 0.05 on log expressions).
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tween blood modulated pathways and the disease eti-
ology and the molecular pathological relationship
between peripheral and central tissues, gene expression
levels were also analyzed in mouse brains (Figure 9).
This investigation revealed that only C3, Tpm2 and
Serping1 were significantly modulated in brain of R6/2,
even if the last one highlighted an opposite behavior
with respect to the one observed in blood; Fabp1
resulted undetectable in brain. Up-regulation of other
serpins was already observed in R6/2 brain and other tis-
sues as well as in patients brain [54]. In addition, C3
mRNA increment in R6/2 brains mirrored results of
transcriptional investigations displaying an increased
complement biosynthesis in different brain areas of HD
patients compared to healthy individuals [28,55] but
again differed from Larkin et al. [49] that did not ob-
serve significant C3 expression modulation in R6/2
brain. Our data raise the possibility of therapies targeting
complement components in neurodegenerative disorder,
with probably Serping1 representing, with respect to C3,
a better candidate disease target in terms of drug devel-
opment, and a potential biomarker [30,31].
In conclusion, all these findings enforce the hypothesis
that immunological alteration may contribute to neuro-
logical degeneration and components of this pathway
may represent potential biomarkers to monitor in paral-
lel drug efficacy in periphery and in brain, supporting
the usefulness of this model in pre-clinical studies.
Conclusion
HD is a neurological and devastating disorder with an
urgent need of effective therapies and well established
biomarkers. Even though major efforts in finding periph-
eral disease progression biomarkers are pursued inFigure 9 RT-qPCR in brain. Normalized expression levels of
selected genes showed that C3 and Serping1 were modulated but in
opposite direction, and Tmp2 was down-regulated. Fabp1 was not
detectable (N.D.) (*Student’s t-test p < 0.05 on log expressions).human studies, the availability of validated animal dis-
ease models is of great aid in all pre-clinical studies
aimed at moving ahead promising compounds into clin-
ical studies, evaluating their possible molecular mechan-
ism of action. In addition, transcriptional analysis on
these models could unveil novel therapeutic targets re-
lated to the pathology onset and progression.
On the other side, one of the major drawbacks for
in-vivo pathology models is the incomplete correspond-
ence of these with the real human disease situation that
could cause misinterpretation of data, with deleterious
effects on drug discovery progression. Here, we evalu-
ated through a whole genome approach, peripheral
transcriptional alterations of biological pathways in
circulating blood cells of a well characterized HD mouse
model. Our data revealed the direct involvement of
processes that are well known markers of Huntington’s
disease progression in man. Several microarray findings
have been investigated by RT-qPCR in other peripheral
easily accessible tissues and in brain with obvious
projection toward clinical studies. The approach adopted
in this work offers interesting remarks that could be
further investigated in a larger cohort of transgenic
mice at different stages of pathology development and
validated in other HD models to strengthen the findings
on the involvement in HD progression of these bio-
logical pathways obtained by GSEA analysis. Nevertheless,
preliminary results presented here could be considered
a further step in validating the R6/2 mouse model
as first line pre-clinical tool, giving at the same time
an insight of important pathological hallmarks for
Huntington’s disease, and contributing to attractive
novel biomarkers development.
Methods
Mouse handling, blood and tissues collection
This study included four R6/2 male mice (about 110
CAG repeats) and four wild type (WT) male littermates
that were bred at PsychoGenics Laboratories (Tarrytown,
NY, USA). All animals were examined, manipulated, and
weighed prior initiation of the study to assure adequate
health, suitability and to minimize non-specific stress as-
sociated with manipulation. During the course of the
study animals were maintained in a 12/12 light/dark cy-
cles with temperature ranging between 20 and 23°C and
relative humidity around 50%. Chow and water were
provided ad libitum for the duration of the study. Geno-
type was determined by PCR analysis of DNA tail,
performed at PsychoGenics Laboratories.
Mice were sacrificed at the age of 16 weeks. Terminal
whole blood samples were collected via closed cardiac
puncture on anesthetized live mouse (CO2). Blood sam-
ples were drawn by sterile syringe and 100 μl were dir-
ectly transferred to RNAprotect Animal Blood Tubes
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turer indications and maintained at −80°C. In addition,
the following organs were collected: brain with cerebel-
lum, skeletal muscle (quadriceps) and skin (a strip of
about 1 cm × 3 cm of the abdominal area).
All experiments on mice were carried out in strict ac-
cordance with the recommendations of the Guide for
the Care and Use of Laboratory Animals. The protocol
was approved by the Institutional Animal Care and Use
Committee of PsychoGenics, Inc. (PHS OLAW animal
welfare assurance number A4471-01), an AAALAC
International accredited institution (Unit #001213).
RNA purification
Total RNA was purified from whole blood by RNeasy
Protect animal blood kit (QIAGEN GmbH, Hilden,
Germany) according to the instruction provided with
the kit. Purified RNA was quantified by Nanodrop ND-
1000 Spectrophotometer and checked for RNA integ-
rity by Bioanalyzer (Agilent Technologies, Palo Alto,
CA). All samples with RIN between 8.40 and 9.0
were included in the subsequent investigations: RNA
obtained from blood of a wild type mouse did not sat-
isfy quality control and was excluded from transcrip-
tional investigations (RIN = 7.50).
Total RNA was extracted from brain (ensuring to dis-
sect exactly the same portion, including striatum and
cortex), skeletal muscle, and skin after shaving using
RNeasy Lipid Tissue Mini kit (QIAGEN) following the
instruction provided by the kit.
To assess RNA integrity (28S and 18S ribosomal RNA
bands) all samples were loaded on agarose gel with Eth-
idium Bromide (Sigma-Aldrich Corporation, MO, USA)
and quantified by NANODROP 2000 spectrophotometer
(Thermo Fischer Scientific, MA, USA).
Gene expression analysis
Microarray
Microarray experiment was performed on individual
blood samples, 500 ng of total RNA of each sample was
employed to generate target RNA or amplified RNA
(aRNA). This aRNA was then hybridized onto GeneChip®
Mouse Genome 430 2.0. This array comprises overTable 3 Complete primer sequences and gene bank accession
Gene symbol Ref seq Primer





Tmp2 NM_009416 AGCCCA45,000 probe sets representing more than 34,000 well-
substantiated mouse genes. Microarrays experiment
was performed by Precision Biomarker Resources, Inc.
(Evanston, IL, USA).
RT-qPCR
Before cDNA synthesis, the same quantity of RNAs
derived from every blood sample of each strain was
pooled together obtaining a single pooled sample of wild
type mice blood and a single pooled sample of mutant
mice blood. The two deriving pools were quantified by
NANODROP 2000 Spectrophotometer (Thermo Fischer
Scientific, MA, USA). cDNA was synthesized from 1 μg
of RNA obtained from blood pooled samples as well as
from all the other individual tissues (brain, skeletal
muscle and skin), by using QuantiTect Reverse Tran-
scription kit (QIAGEN GmbH, Hilden, Germany) and
diluted to 100 μL.
RT-qPCRs on cDNA samples were performed using a
CFX96 Real Time System/C1000 Thermal cycler (Bio-
Rad Hercules, CA, USA) with iQ™ SYBR Green master
mix 2X (Bio-Rad) with primers that specifically ampli-
fied target or control genes. The run protocol used in
RT-qPCR was the “2 step amplification”, with annealing
temperature tailored on the primer pair used. Each run
was followed by Melting Curve run and analysis to con-
firm amplification of a single product.
The primers were designed using Beacon Designer 7.9
software (PREMIER Biosoft International, CA, USA),
employing sequences data from NCBI database or from
published validated sequences. To guarantee primer spe-
cificity, they were checked with NCBI BLAST against
Reference RNA sequence (Refseq_rna) of Mus musculus.
Primers were defined inside the region targeted by
Affymetrix probe sets. Complete primer sequences, gene
bank accession numbers are shown in Table 3. RT-qPCR
expression data on blood samples were normalized on
geometric mean of Ppib, Actb, Ywhaz and Rpl13a, as de-
scribed elsewhere [16]. Moreover, Actb, B2m, Hprt, and
Rpl13a were employed for the other tissues, except Actb
in skeletal muscle (due to low stability, data not shown).
Reference gene primer sequences were taken from
Diamanti et al. [16].numbers of selected genes analyzed in RT-qPCR
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Affymetrix CEL files were analyzed with R program (The
R Project for Statistical Computing http://www.r-project.
org/) by making use of Bioconductor packages (http://
www.bioconductor.org). Normalization for quantitative
comparison of different microarrays was performed with
quantiles within the RMA package [56-58] and final ex-
pression values were calculated by summarizing probe
set intensities with median-Polish algorithm. Differen-
tial expression analysis between four mutant and three
wild type samples was tested with LIMMA package
[59]. Correction for multiple testing was not performed
due to the low number of arrays.
In RT-qPCR, relative expressions, obtained from Cq
corrected by amplification efficiency, were normalized
on geometric mean of selected reference gene expression
values [16].
Differentially modulated genes in brain, skin and muscle
among mutant and wild type samples were identified
with Student’s t-test on logarithmic transformed expres-
sions, p-values below 0.05 were considered statistically sig-
nificant. No statistical test was applied on blood samples,
because these samples were pooled in RT-qPCR investiga-
tions. Statistical analysis of RT-qPCR data was performed
in GraphPad Prism 5.
Gene set enrichment analysis of microarray data was
performed using GSEA 2.07 software ( [60], http://www.
broadinstitute.org/gsea/index.jsp) and using MSigDB v
3.1, focusing attention on the following collections: C2
BioCarta gene sets, C2 KEGG gene sets, C2 Reactome
gene sets and C5 GO Biological Processes. Software de-
fault parameters were used, except for permutation
type parameter that was set to “permutation on gene
set” due to the low number of arrays employed. Gene
sets with false discovery rate (FDR) less than 0.25 were
considered significant.
KEGG pathways were downloaded and processed in
R/Bioconductor by using Pathview package [61].Additional files
Additional file 1: Enriched GO Biological Process collection.
Description: Table showed Biological Processes enriched in R6/2 (in red)
or in WT (in green) and GSEA results.
Additional file 2: Complement and Coagulation Cascades Pathway
members part of the core enrichment. Description: Annotations of
genes with corresponding Affy Id are reported together with GSEA
statistic (enrichment score, ES) and LIMMA statistics (fold change, FC,
and p-value.
Additional file 3: PPAR Signaling Pathway members part of the
core enrichment. Description: Annotations of genes with corresponding
Affy Id are reported for PPAR signaling pathway; GSEA statistic
(enrichment score, ES) and LIMMA statistics (fold change, FC, and
p-value) are also showed.
Additional file 4: Cardiac Muscle Contraction Pathway members
part of the core enrichment. Description: Annotations of genes withcorresponding Affy Id are reported together with GSEA statistic
(enrichment score, ES) and LIMMA statistics (fold change, FC, and
p-value) for Cardiac Muscle Contraction pathway.
Additional file 5: Dilated Cardiomyopathy Pathway members part
of the core enrichment. Description: Annotations of genes with
corresponding Affy Id are reported together with GSEA statistic
(enrichment score, ES) and LIMMA statistics (fold change, FC, and
p-value) for Dilated Cardiomyopathy pathway.
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